AWM
SIOX

Aevitas Wealth Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Aevitas Wealth Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-81
Closed -$2K – 465
2018
Q3 		$2K Hold
81
– – ﹤0.01% 428
2018
Q2 		$1K Sell
81
-125
-61% -$1.84K ﹤0.01% 424
2018
Q1 		$2K Hold
206
– – ﹤0.01% 415
2017
Q4 		$9K Buy
+206
New +$9.24K 0.01% 334

Other funds holding SIOX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aevitas Wealth Management's SIOX Position: Q4 2018 in Review

Aevitas Wealth Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2018, closing a stake of 81 shares — an estimated $2K sold.

Aevitas Wealth Management first reported a position in SIOX in Q4 2017 and held it in 4 quarters. The position peaked at $9K in Q4 2017. 61 funds tracked by Wall St. Rank hold SIOX as of Q4 2018.

  • Aevitas Wealth Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Aevitas Wealth Management sold 81 Sio Gene Therapies Inc. Common Stock shares in Q4 2018, an estimated $2K.
  • Aevitas Wealth Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Aevitas Wealth Management's Sio Gene Therapies Inc. Common Stock position peaked at $9K in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2018.

Based on Aevitas Wealth Management's 13F filing for Q4 2018, filed 14 Feb 2019.